Managing stone recurrence: What practitioners should know
In this interview, Juan Calle, MD, discusses how he follows patients once they are stone free and how he utilizes dietary/lifestyle modification and medical management.
Related Articles
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
“[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations,”…
Exploring Treatments for Metastatic Castration-Sensitive Prostate Cancer
Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient…
How to bill for placement of a peri-rectal spacer
“Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable…
Adam Lorentz, MD, on predictions for future advances in robotics
“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD,…
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who…
Raveen Syan, MD, shares 2025 Urology on the Beach highlights
“I know this year we’re going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes,…
Standard pathology reports may be difficult to understand for patients with prostate cancer
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had…
Health-related QOL is comparable among ARPI regimens for CSPC
At 25 weeks, FACT-P total score remained comparable between the arms.
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
“[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations,”…
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
“The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial…